These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 6423661)

  • 1. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men.
    Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D
    J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration.
    Pavlou SN; Dahl KD; Wakefield G; Rivier J; Vale W; Hsueh AJ; Lindner J
    J Clin Endocrinol Metab; 1988 May; 66(5):1005-9. PubMed ID: 2834409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
    Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men.
    Crowley WF; Beitins IZ; Vale W; Kliman B; Rivier J; Rivier C; McArthur JW
    N Engl J Med; 1980 May; 302(19):1052-7. PubMed ID: 6767977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the luteinizing hormone-releasing hormone (LHRH) analog D-Trp6-Pro9-NEt-LHRH on the pituitary-gonadal axis of prepubertal rhesus monkeys.
    Cassorla F; Renquist D; Barnard D; Munabi AK; Cutler GB; Loriaux DL
    Biol Reprod; 1984 Jun; 30(5):1130-4. PubMed ID: 6428479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man.
    Evans RM; Doelle GC; Lindner J; Bradley V; Rabin D
    J Clin Invest; 1984 Jan; 73(1):262-6. PubMed ID: 6228566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pituitary-testicular axis suppression in utero and during the early neonatal period with a long-acting luteinizing hormone-releasing hormone analog on genital development, somatic growth, and bone density in male cynomolgus monkeys in the first 6 months of life.
    Liu L; Cristiano AM; Southers JL; Reynolds JC; Bacher J; Brown G; Gilley RM; Tice TR; Banks SM; Loriaux LD
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1038-43. PubMed ID: 1939516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone.
    Pavlou SN; Interlandi JW; Wakefield G; Rivier J; Vale W; Rabin D
    J Androl; 1986; 7(4):228-33. PubMed ID: 3528106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men.
    Finkelstein JS; Whitcomb RW; O'Dea LS; Longcope C; Schoenfeld DA; Crowley WF
    J Clin Endocrinol Metab; 1991 Sep; 73(3):609-20. PubMed ID: 1908484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropins and testosterone escape from suppression during prolonged luteinizing hormone-releasing hormone antagonist administration in normal men.
    Pavlou SN; Interlandi JW; Wakefield G; Island DP; Rivier J; Vale W; Kovacs WJ
    J Clin Endocrinol Metab; 1987 May; 64(5):1070-4. PubMed ID: 3104387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of deslorelin dose in the treatment of central precocious puberty.
    Pescovitz OH; Barnes KM; Cutler GB
    J Clin Endocrinol Metab; 1991 Jan; 72(1):60-4. PubMed ID: 1898743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential control of luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man.
    Gross KM; Matsumoto AM; Bremner WJ
    J Clin Endocrinol Metab; 1987 Apr; 64(4):675-80. PubMed ID: 3102545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting suppresses pulsatile luteinizing hormone (LH) secretion and enhances orderliness of LH release in young but not older men.
    Bergendahl M; Aloi JA; Iranmanesh A; Mulligan TM; Veldhuis JD
    J Clin Endocrinol Metab; 1998 Jun; 83(6):1967-75. PubMed ID: 9626127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of pituitary-testicular function with [D-Trp6] luteinizing hormone-releasing hormone in rhesus monkeys.
    Sundaram K; Connell KG; Bardin CW; Samojlik E; Schally AV
    Endocrinology; 1982 Apr; 110(4):1308-14. PubMed ID: 6460610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.